P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA

Bibliographic Details
Main Authors:	E. Monzón Manzano, M. T. Alvarez Román, P. Acuña, E. G. Arias Salgado, A. Ramírez, M. Martín Salces, M. I. Rivas Pollmar, A. González Ceberino, N. V. Butta, V. Jiménez Yuste
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000849520.34461.74

Similar Items

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
by: Olga S. Levchenkova, et al.
Published: (2023-03-01)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
by: José María Bastida, et al.
Published: (2021-04-01)

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists
by: Kathy M. Nilles, et al.
Published: (2019-11-01)

P1656: EVALUATION OF PLATELET FUNCTION IN RARE OR UNDIAGNOSED BLEEDING DISORDERS
by: P. Acuña Butta, et al.
Published: (2022-06-01)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
by: Hanny Al-Samkari, et al.
Published: (2019-04-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
by: Jiwon Shin, et al.
Published: (2023-05-01)

Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia
by: Jundong Zhang, et al.
Published: (2023-04-01)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
by: José R. González-Porras, et al.
Published: (2019-03-01)

S296: IN VITRO ANALYSIS OF THE IMPACT OF INHIBITORS ON THE PROCOAGULANT EFFECTS OF BYPASS AGENTS OR HEMOSTATIC FACTORS IN COMBINATION WITH EMICIZUMAB
by: A. Dos Santos Ortas, et al.
Published: (2022-06-01)

P1661: THROMBOPATHY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND AUTOIMMUNE DISEASE
by: E. Garcia Perez, et al.
Published: (2022-06-01)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
by: Nikki Agarwal, et al.
Published: (2021-03-01)

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice
by: V V PTUSHKIN, et al.
Published: (2018-07-01)

Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia
by: Lamya Garabet, et al.
Published: (2019-02-01)

Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists
by: Lamya Garabet, et al.
Published: (2020-02-01)

Perspectives of vitamin C upregulating regulatory T cells in the era of thrombopoietin receptor agonists for immune thrombocytopenia
by: Shiu Ying Tsao
Published: (2022-12-01)

European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia
by: Adele Barlassina, et al.
Published: (2023-02-01)

Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review
by: Simone Birocchi, et al.
Published: (2021-02-01)

Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists
by: Lamya Garabet, et al.
Published: (2020-04-01)

P1636: PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).
by: A. G. Jansen, et al.
Published: (2022-06-01)

Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study
by: Alexander Åkesson, et al.
Published: (2023-12-01)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
by: S. Dangudubiyyam, et al.
Published: (2022-06-01)

PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY
by: A. Åkesson, et al.
Published: (2022-06-01)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
by: Gamal Sayed, et al.
Published: (2023-08-01)

Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)
by: A. J. Gerard Jansen, et al.
Published: (2023-12-01)

Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort
by: Alessandro Lucchesi, et al.
Published: (2023-12-01)

Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP)
by: Sif Gudbrandsdottir, et al.
Published: (2017-07-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)
by: Rick Kapur, et al.
Published: (2020-04-01)

The Importance of Platelet Glycoside Residues in the Haemostasis of Patients with Immune Thrombocytopaenia
by: Andrés Ramírez-López, et al.
Published: (2021-04-01)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
by: Celia Martinez, et al.
Published: (2023-08-01)

The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity
by: Eman Mostafa Hamed, et al.
Published: (2023-06-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2018-01-01)

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
by: Adam Cuker, et al.
Published: (2021-01-01)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
by: Kensaku Nakai, et al.
Published: (2022-02-01)

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently
by: Mohamed A. Yassin, et al.
Published: (2023-12-01)

P1629: DISCONTINUATION OF TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER CLINICAL EXPERIENCE
by: Ana María Mena Santano, et al.
Published: (2023-08-01)

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
by: Heng Mei, et al.
Published: (2021-02-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01)

Serum thrombopoietin and cMpl expression in thrombocytopenia of different etiologies
by: Fabrizio Vianello, et al.
Published: (2014-03-01)